4106 results about "Gastroenterology" patented technology

Bifurcated, active fixation, gastrointestinal leads adapted to be implanted within the body at a site of the GI tract to conduct electrical stimulation and electrical signals of the GI tract between the gastrointestinal stimulator and the site are disclosed. The GI tract lead has a lead body comprising a common lead body trunk extending from a lead body trunk proximal end to a junction with a first plurality of lead body legs that extend from the junction to a like first plurality of lead body leg distal ends. An electrode head is formed at each lead body leg distal end having a plate and supporting at least one stimulation/sense electrode and an active fixation mechanism, whereby a plurality of active fixation attachment mechanisms are supported by a like plurality of electrode heads. The plurality of electrode heads can be affixed by the fixation mechanism at a plurality of spaced apart locations of the GI tract. The plurality of electrode heads can be affixed spaced apart an optimal distance for efficacious sensing and/or stimulation accommodating the physiology and any defects or surgical interventions of the physiology or other therapeutic equipment or IMDs that restrict full access to the GI tract.

Methods and systems for delivering or placing a gastrointestinal implant device into a mammal. The gastrointestinal implant device can be used to limit absorption of food products in specific parts of the digestive system and can include a gastrointestinal sleeve having an anchor portion and a barrier or sleeve portion. The methods include endoluminal delivery of the device.

Methods for treating metabolic disorders, including diabetes and obesity, using TNFalpha inhibitors are described.

In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.

Methods and devices for treating obesity by combining known bariatric surgeries with a method for disrupting the vagal nerve. The method for disrupting the vagal nerve comprises use of a high energy delivery device which is positioned within the esophagus to deliver transesophageal energy to interrupt the function of one or both branches of the vagal nerves. Combination of this method with known methods, such as gastric bypass and gastric banding, may increase weight loss by the patient in comparison to a single treatment on its own. In addition, methods and devices for disposing a restrictive structure such as a mesh around a selected segment of the gastrointestinal tract prevents enlargement of the segment.

Active fixation, gastrointestinal leads adapted to be implanted within the body at a site of the GI tract to conduct electrical stimulation from an implantable or external gastrointestinal stimulator to the site and to conduct electrical signals of the GI tract from the site to the implantable or external gastrointestinal stimulator are disclosed. Disclosed active fixation mechanisms include one or more of hooks, and helixes extending from stops, e.g. plates, of an electrode head and functioning as stimulation/sense electrodes in unipolar and bipolar configurations or simply as fixation mechanisms. The active fixation mechanisms are coated to reduce inflammation and polarization effects.

Methods of treating, preventing and/or managing an immunodeficiency disease or disorder are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active agent. Methods of boosting humoral immunity are also disclosed.

The invention provides methods, uses and compositions for the treatment of psoriatic arthritis. The invention describes methods and uses for treating psoriatic arthritis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to psoriatic arthritis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment of psoriatic arthritis in a subject.

A computerized method of analyzing measurements obtained from the gastrointestinal tract of subject comprising the steps of providing an ingestible capsule (20) having a sensor (22, 23, 24) for measuring a parameter of the gastrointestinal tract of a subject, having a subject ingest (118) the capsule, recording (130) measurements from the sensor as the capsule passes through the gastrointestinal tract of the subject, transmitting (131, 122) the measurements to a processor (31), conditioning (132) the measurements to provide data as a function of a time interval, plotting (133) the data on a display (32), providing a query (205, 216, 234), on the display, receiving input (207, 218, 237) from a user in response to the query, setting a marker (50-53) on the plot (40) at a location as a function of the input, and determining (238) a capsule transit time for a selected portion of the gastrointestinal tract as a function of the location of the marker.

The present invention provides methods and compositions for the treatment of phospholipase-related conditions. In particular, the invention provides a method of treating insulin-related, weight-related conditions and/or cholesterol-related conditions in an animal subject. The method generally involves the administration of a non-absorbed and/or effluxed phospholipase A2 inhibitor that is localized in a gastrointestinal lumen.

Methods of treating, preventing or managing leukemias are disclosed. The methods encompass the administration of an immunomodulatory compound of the invention known as Revlimid® or lenalidomide. The invention further relates to methods of treatment using this compound with chemotherapy, radiation therapy, hormonal therapy, biological therapy or immunotherapy. Pharmaceutical compositions and single unit dosage forms suitable for use in the methods of the invention are also disclosed.

The present invention relates to compositions for the treatment of conditions, including pancreatic insufficiency. The compositions of the present invention comprise lipase, protease and amylase in a particular ratio that provides beneficial results in patients, such as those afflicted with pancreatic insufficiency. This invention also relates to methods using such compositions for the treatment of pancreatic insufficiency.

Devices and methods are provided for ablational treatment of regions of the digestive tract in post-bariatric surgery patients who fail to achieve or maintain the desired weight loss. Bariatric procedures include Roux-en-Y gastric bypass, biliopancreatic diversion, and sleeve gastrectomy. These procedures reconstruct gastrointestinal tract features, creating pouches, stoma, and tubes that restrict and/or divert the digestive flow. Post-surgical dilation of altered structures is common and diminishes their bariatric effectiveness. Ablation of compromised structures can reduce their size and compliance, restoring bariatric effectiveness. Ablation, as provided the invention, starts at the mucosa and penetrates deeper into the gastrointestinal wall in a controlled manner. Control may also be provided by a fractional ablation that ablates some tissue within a target region and leaves a portion substantially unaffected. Embodiments of the device include an ablational electrode array that spans 360 degrees and an array that spans an arc of less than 360 degrees.

A method and a multichannel implantable device are described for partial or complete restoration of impaired gastrointestinal motility, or for disturbing and/or partially or completely blocking normal gastrointestinal motility using one or multiple microsystem-controlled channels of circumferentially arranged sets of two or more electrodes which provide externally-invoked synchronized electrical signals to the smooth muscles via the neural pathways.

Disclosed herein are methods and low dose regimens for increasing fetal hemoglobin levels in patients with red blood cell disorders, such as beta thalassemia, sickle cell disease, other anemias, or blood loss. Fetal and total hemoglobin levels and red blood cell counts are increased by administering 2,2-dimethylbutyrate (DMB) alone or in combination with hydroxyurea, decitabine or an HDAC inhibitor. Treatment can be continued for at least two weeks.

Provided herein are methods of utilizing bile acid transport inhibitors for the treatment of obesity and diabetes.

Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes. A method for assessing diabetes includes identifying the presence of diabetic dyslipidemia based on the values of predetermined NMR measured lipoprotein constituents.

The present invention relates to use of ornithine in the manufacture of a medicament for use in combination with at least one of phenylacetate and phenylbutyrate for preventing or treating liver decompensation or hepatic encephalopathy. The invention also relates to use of at least one of phenylacetate and phenylbutyrate in the manufacture of a medicament for use in combination with ornithine for preventing or treating liver decompensation or hepatic encephalopathy.

Systems and methods are disclosed for treatment of metabolic disorders such as type 2 diabetes and obesity by stimulation of the small intestine to modulate hormone production. Methods include applying an appropriate signal to a region of the small intestine to modulate hormone production. The method may involve applying a signal to the nerves that innervate the small intestine. Devices for delivering the signal are disclosed.

The invention provides methods, uses and compositions for the treatment of hidradenitis suppurativa. The invention describes methods and uses for treating hidradenitis suppurativa, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat hidradenitis suppurativa in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treating hidradenitis suppurativa in a subject.